SE0006091997
© PR Newswire
02.04.2025
IMMNOV
LISTED
STO
Immunovia publishes the Annual Report for 2024
News Preview
LUND, Sweden, April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published.
The annual report can be downloaded in pdf format and is available on Immunovia's website.
For more information, please contact:
Jeff Borcherding CEO and President jeff.borcherding@immunovia.com
Immunovia in brie...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
IMMNOV
LISTED
STO
The exercise period for warrants series TO 3 begins today
News Preview
LUND, Sweden, April 1, 2025 /PRNewswire/ -- Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025.
Summarized terms for the warrants of series TO 3
Structure: One (1) warrant series TO 3 entitles the ho...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 3
News Preview
LUND, Sweden, March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in t...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
24.03.2025
IMMNOV
LISTED
STO
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
21.03.2025
IMMNOV
LISTED
STO
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.
Jeff Borch...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
IMMNOV
LISTED
STO
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of st...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
IMMNOV
LISTED
STO
Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference
News Preview
LUND, Sweden, March 3, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week® (DDW) 2025 conference, taking place May 5, 2025.
The CLARITI study w...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
IMMNOV
LISTED
STO
Immunovia Publishes Full Year Report for 2024
News Preview
LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October-December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc.Operating losses were -30...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
IMMNOV
LISTED
STO
Immunovia initiates search for a new CFO to support commercialization in the USA
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market.
As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial lead...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
IMMNOV
LISTED
STO
Invitation to Immunovia's Q4 presentation
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com.
Jeff Borcherding, CEO and P...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
News Preview
LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863.
For further information, please contactJeff Bo...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
News Preview
LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863.
For further information, please contact:Jeff B...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.01.2025
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2025
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.
According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.
According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025.
Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025.
Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
IMMNOV
LISTED
STO
Immunovia discovery study published in top protein research journal
News Preview
LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
IMMNOV
LISTED
STO
End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
News Preview
LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025.
In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success
As 2024 began, we had recently completed a significant transformation...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
IMMNOV
LISTED
STO
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
News Preview
LUND, Sweden, Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024.
Immunovia CEO Jeff Borcherding, one of the company's largest sha...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
IMMNOV
LISTED
STO
Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.
Jeff Borcherdi...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
IMMNOV
LISTED
STO
Immunovia announces financial calendar for financial year 2025/2026
News Preview
LUND, Sweden, Dec. 11, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026.
Year-End 2024 Report February 25, 2025
Q1 Report, 2025 May 14, 2025
Q2 Report, 2025 ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
IMMNOV
LISTED
STO
Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
News Preview
LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
In the study of over 1,000 pa...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2024
IMMNOV
LISTED
STO
Immunovia to present at the Redeye Technology & Life Science Day
News Preview
LUND, Sweden, Nov. 28, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye.
Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking wo...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
IMMNOV
LISTED
STO
Immunovia Publishes Interim Report for January-September 2024
News Preview
LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1 MSEK (-38.6).Earnings per share before and after dilution were -0.73 SEK (-0.91).Cash flow from operating activities amounted to -21.2 MSEK (-35.6).Cash and cash equi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
IMMNOV
LISTED
STO
Immunovia Publishes Interim Report for January-September 2024
News Preview
LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1 MSEK (-38.6).Earnings per share before and after dilution were -0.73 SEK (-0.91).Cash flow from operating activities amounted to -21.2 MSEK (-35.6).Cash and cash equi...
Themefolio
Profiler
Peergroup
© PR Newswire
15.11.2024
IMMNOV
LISTED
STO
Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers
News Preview
PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company's next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC)....
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
IMMNOV
LISTED
STO
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfull...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
IMMNOV
LISTED
STO
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfull...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
